| 0.7 0.03 (4.48%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.91  |
1-year : | 1.06 |
| Resists | First : | 0.77 |
Second : | 0.91 |
| Pivot price | 0.71 |
|||
| Supports | First : | 0.65 |
Second : | 0.56 |
| MAs | MA(5) : | 0.68  |
MA(20) : | 0.7 |
| MA(100) : | 0.7 |
MA(250) : | 1.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 27.1 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 2.05 | Low : | 0.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OCGN ] has closed above bottom band by 36.4%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.71 | 0.71 - 0.71 |
| Low: | 0.66 - 0.67 | 0.67 - 0.67 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Mon, 12 May 2025
Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus
Mon, 12 May 2025
Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus
Mon, 12 May 2025
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga
Sat, 10 May 2025
Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Sat, 10 May 2025
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo Finance
Fri, 09 May 2025
Ocugen: Q1 Earnings Snapshot - MySA
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 292 (M) |
| Held by Insiders | 2.8737e+008 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 67,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.279e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 811.5 % |
| Return on Equity (ttm) | -46.6 % |
| Qtrly Rev. Growth | 4.05e+006 % |
| Gross Profit (p.s.) | -10.83 |
| Sales Per Share | -36.41 |
| EBITDA (p.s.) | -6.63593e+006 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 29.6 |
| Dividend | 0 |
| Forward Dividend | 6.867e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|